Review of Bone Modifying Agents in Metastatic Breast Cancer.
bone modifying agents
metastatic breast cancer
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
13 Feb 2021
13 Feb 2021
Historique:
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Bone is the most common site for distant metastases in breast cancer and can cause significant morbidity and mortality. Bone modifying agents (BMAs) that include bisphosphonates (BPAs) and denosumab help in decreasing and delaying skeletal-related events (SREs) associated with metastatic breast cancer. BPAs approved for use by the Food and Drug Administration (FDA) in bone metastases (BM) in the United States are pamidronate and zolendronic acid, while clodronate and ibandronate are licensed for use in other countries. Current American Society of Clinical Oncology (ASCO) guidelines recommend denosumab 120 mg subcutaneously every four weeks, or zolendronic acid 4 mg every four weeks or every 12 weeks, or intravenous pamidronate 90 mg every four weeks. Current guidelines do not recommend one BMA over another, however, zolendronic acid and denosumab were the most commonly used BMAs in population-based studies. Side effects of BMAs include acute phase reactions, hypocalcemia, nephrotoxicity, osteonecrosis of jaw, etc. While other side effects are common with both BPAs and denosumab, the latter has less nephrotoxic potential and is preferred for use in patients with renal failure. Current ASCO guidelines recommend continuing BMAs indefinitely, however, in clinical practice, this decision needs to be individualized, especially since there is no data on the impact of long-term use of BMAs. Further studies would need to be developed to develop an algorithm of SRE risk assessment and to determine which patients would benefit from BMAs.
Identifiants
pubmed: 33738175
doi: 10.7759/cureus.13332
pmc: PMC7960030
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e13332Informations de copyright
Copyright © 2021, Raghu Subramanian et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Future Oncol. 2014 Feb;10(2):257-75
pubmed: 24490612
Breast Cancer Res Treat. 2010 Oct;123(3):781-3
pubmed: 20690039
Oncologist. 2005 Jan;10(1):52-62
pubmed: 15632252
Eur J Cancer. 2000 Mar;36(4):476-82
pubmed: 10717523
Clin Cancer Res. 2013 Dec 15;19(24):6863-72
pubmed: 24166910
Clin Cancer Res. 2008 Oct 15;14(20):6690-6
pubmed: 18927312
J Clin Oncol. 2011 Sep 10;29(26):3591-2; author reply 3592-3
pubmed: 21844502
J Oncol Pract. 2011 Mar;7(2):117-21
pubmed: 21731520
Crit Rev Oncol Hematol. 2017 Jul;115:67-80
pubmed: 28602171
Front Oncol. 2019 Aug 14;9:774
pubmed: 31475116
Breast Care (Basel). 2014 Oct;9(5):332-6
pubmed: 25759613
J Clin Oncol. 1996 Sep;14(9):2552-9
pubmed: 8823335
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Palliat Med. 2017 Jan;31(1):5-25
pubmed: 27006430
J Clin Oncol. 2017 Dec 10;35(35):3978-3986
pubmed: 29035643
J Clin Oncol. 2010 Dec 10;28(35):5132-9
pubmed: 21060033
J Cancer Res Clin Oncol. 2008 Dec;134(12):1303-10
pubmed: 18504612
BMC Cancer. 2005 Jul 28;5:89
pubmed: 16048654
Curr Oncol. 2006 Oct;13(5):187-90
pubmed: 22792016
Eur J Cancer. 2015 Sep;51(13):1812-21
pubmed: 26093811
Crit Rev Oncol Hematol. 2019 May;137:1-8
pubmed: 31014505
Ann Oncol. 2015 Nov;26(11):2205-13
pubmed: 26122727
Med Care. 2004 Feb;42(2):164-75
pubmed: 14734954
Onco Targets Ther. 2016 Jul 08;9:4173-80
pubmed: 27468239
Curr Breast Cancer Rep. 2018;10(4):241-250
pubmed: 30581537
Am J Hosp Palliat Care. 2015 Aug;32(5):568-72
pubmed: 24928835
JAMA Oncol. 2017 Jul 1;3(7):906-912
pubmed: 28125763
Support Care Cancer. 2005 Dec;13(12):975-86
pubmed: 15871033
Int J Clin Pract. 2012 Dec;66(12):1139-46
pubmed: 22967310
Ann Oncol. 2006 Jun;17(6):897-907
pubmed: 16547070
Oncologist. 2015 Apr;20(4):440-9
pubmed: 25732263
Lancet Oncol. 2014 Jan;15(1):114-22
pubmed: 24332514
J Clin Oncol. 2017 Dec 10;35(35):3949-3955
pubmed: 29023215
J Bone Oncol. 2017 Nov 24;11:1-9
pubmed: 29892519
Oncotarget. 2016 Mar 15;7(11):12612-22
pubmed: 26871471
J Clin Oncol. 1993 Mar;11(3):491-8
pubmed: 7680374
Int J Clin Oncol. 2013 Jun;18(3):531-8
pubmed: 22572805
Cancer. 2003 Oct 15;98(8):1735-44
pubmed: 14534891
BMC Cancer. 2011 Jan 24;11:29
pubmed: 21261987
Asia Pac J Clin Oncol. 2017 Aug;13(4):266-276
pubmed: 27862983
Br J Cancer. 1987 Jan;55(1):61-6
pubmed: 3814476
J Clin Oncol. 2009 Apr 1;27(10):1564-71
pubmed: 19237632
Oncol Lett. 2014 Jun;7(6):1997-2002
pubmed: 24932278
Lancet Oncol. 2013 Jun;14(7):663-70
pubmed: 23684411
J Clin Oncol. 1993 Jan;11(1):59-65
pubmed: 8418243